APA Цитирование

Hew, K. E., Miller, P. C., El-Ashry, D., Sun, J., Besser, A. H., Ince, T. A., . . . Simpkins, F. (2015). MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in high grade serous ovarian cancer. Clin Cancer Res.

Chicago-стиль цитирования

Hew, Karina E., et al. "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in High Grade Serous Ovarian Cancer." Clin Cancer Res 2015.

MLA-цитирование

Hew, Karina E., et al. "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in High Grade Serous Ovarian Cancer." Clin Cancer Res 2015.

Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.